This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tissing, W. J.E. Articles by Pieters, R. Search for Related Content PubMed PubMed Citation Articles by Tissing, W. J.E. Articles by Pieters, R.

Genetic Variations in the Glucocorticoid Receptor Gene Are Not Related to Glucocorticoid Resistance in Childhood Acute Lymphoblastic Leukemia

Authors' Affiliations: ¹ Department of Pediatric Oncology/Hematology, Erasmus Medical Center/Sophia Children's Hospital; ² Endocrinology and ³ Hematology, Erasmus Medical Center, Rotterdam, the Netherlands; and ⁴ Dutch Childhood Oncology Group, the Hague, the Netherlands

Requests for reprints: Jules P.P. Meijerink, Erasmus Medical Center/Sophia Children's Hospital, Rotterdam, Dr. Molewaterplein 60, 3015 GJ, Rotterdam, the Netherlands. Phone: 31-10-408-9379; Fax: 31-10-408-9433; E-mail: j.meijerink{at}erasmusmc.nl.

Glucocorticoid sensitivity is an important prognostic factor in pediatric acute lymphoblastic leukemia (ALL). For its antileukemic effect, glucocorticoid binds the intracellular glucocorticoid receptor (GR) subsequently regulating transcription of downstream genes. We analyzed whether genetic variations within the GR gene are related to differences in the cellular response to glucocorticoids.

Methods: In leukemic samples of 57 children, the GR gene was screened for nucleotide variations using a PCR/single-strand conformational polymorphism sequencing strategy. Data were linked to in vivo and in vitro glucocorticoid resistance.

Results: No somatic mutations were detected in the GR gene coding region, but six polymorphisms (i.e., ER22/23EK, N363S, BclI, intron mutation 16 bp upstream of exon 5, H588H, and N766N) were identified. In 67% of ALL cases, at least one minor allele of these polymorphisms was detected. Although only borderline significant, the incidence for the N363S polymorphism minor allele was higher (12% versus 6%, P = 0.06) and for the ER22/23EK minor allele lower (4% versus 7.6%, P = 0.1) than in a healthy, comparable population. The different genotypes of the polymorphisms were not related to prednisone resistance. In conclusion, polymorphisms but not somatic mutations in the GR gene coding region occur in leukemic blasts of children with ALL. Our data suggest that these genetic variations are not a major contributor for differences in cellular response to glucocorticoids in childhood ALL. The higher incidence of the N363S minor allele and the lower incidence of the ER22/23EK minor allele in our ALL population as compared with a normal population warrants further research.

This article has been cited by other articles:

				R. Felder-Puig, C. Scherzer, M. Baumgartner, M. Ortner, C. Aschenbrenner, C. Bieglmayer, T. Voigtlander, E. R. Panzer-Grumayer, W. J.E. Tissing, J. W. Koper, et al. Glucocorticoids in the Treatment of Children with Acute Lymphoblastic Leukemia and Hodgkin's Disease: A Pilot Study on the Adverse Psychological Reactions and Possible Associations with Neurobiological, Endocrine, and Genetic Markers Clin. Cancer Res., December 1, 2007; 13(23): 7093 - 7100. [Abstract] [Full Text] [PDF]

				P. S. Bachmann, R. Gorman, R. A. Papa, J. E. Bardell, J. Ford, U. R. Kees, G. M. Marshall, and R. B. Lock Divergent Mechanisms of Glucocorticoid Resistance in Experimental Models of Pediatric Acute Lymphoblastic Leukemia Cancer Res., May 1, 2007; 67(9): 4482 - 4490. [Abstract] [Full Text] [PDF]

				S. Schmidt, J. A. E. Irving, L. Minto, E. Matheson, L. Nicholson, A. Ploner, W. Parson, A. Kofler, M. Amort, M. Erdel, et al. Glucocorticoid resistance in two key models of acute lymphoblastic leukemia occurs at the level of the glucocorticoid receptor FASEB J, December 1, 2006; 20(14): 2600 - 2602. [Abstract] [Full Text] [PDF]